Point72 Asset Management
ITCI

Point72 Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Point72 Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,200
Closed -$3.02M – 2659
2024
Q4 		$3.02M Buy
+36,200
New +$2.97M 0.01% 1101
2019
Q2 		– Sell
-100,000
Closed -$1.22M – 1581
2019
Q1 		$1.22M Buy
+100,000
New +$1.28M 0.01% 783

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Point72 Asset Management's ITCI Position: Q1 2025 in Review

Point72 Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 251,823 shares — an estimated $21M sold.

Point72 Asset Management first reported a position in ITCI in Q1 2015 and held it in 23 quarters. The position peaked at $38M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Point72 Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 251,823 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $21M.
  • Point72 Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 23 quarters.
  • Point72 Asset Management's Intra-Cellular Therapies Inc. position peaked at $38M in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.